ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,524.61
-1.14%
Dow Jones
40,617.16
-1.41%
US Dollar vs MXN
17.9911
1.44%
Brent Oil
83.995
-0.58%
Bitcoin
63,246.19
-1.31%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) Noticias

LXRX

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LXRX
FechaHoraFuenteTítuloSímboloCompañía
16/07/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA ResubmissionNASDAQ:LXRXLexicon Pharmaceuticals Inc
15/07/202407:00GlobeNewswire Inc.New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202416:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202416:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202408:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202408:15GlobeNewswire Inc.Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and DirectorNASDAQ:LXRXLexicon Pharmaceuticals Inc
21/06/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
19/06/202407:00GlobeNewswire Inc.Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes AssociationNASDAQ:LXRXLexicon Pharmaceuticals Inc
18/06/202407:00GlobeNewswire Inc.Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of CardiologyNASDAQ:LXRXLexicon Pharmaceuticals Inc
14/06/202407:00GlobeNewswire Inc.Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes AssociationNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/05/202406:30GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
15/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LXRXLexicon Pharmaceuticals Inc
14/05/202416:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
14/05/202406:00GlobeNewswire Inc.New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection FractionNASDAQ:LXRXLexicon Pharmaceuticals Inc
10/05/202416:14Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
09/05/202406:30GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
02/05/202415:05GlobeNewswire Inc.Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/04/202408:00GlobeNewswire Inc.Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/04/202406:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
18/04/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host 2024 Investor DayNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/04/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
25/03/202408:20GlobeNewswire Inc.Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/03/202407:00GlobeNewswire Inc.New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202415:25Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202406:15GlobeNewswire Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202406:05GlobeNewswire Inc.Lexicon Announces Oversubscribed $250 Million Private Placement of Equity SecuritiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202406:00GlobeNewswire Inc.Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDANASDAQ:LXRXLexicon Pharmaceuticals Inc
08/01/202406:00GlobeNewswire Inc.Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202316:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
21/12/202315:15GlobeNewswire Inc.Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LXRX

Su Consulta Reciente

NYSE
MCD
McDonalds
FX
USDMXN
US Dollar vs MXN
PM
XAUUSD
Gold vs US Dollar
CCOM
US30
US 30
CCOM
OILBRENT
Brent Oil
CCOM
US500
US 500
COIN
SOLUSD
Solana
NYSE
BAC
Bank of America
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
USOTC
BASFY
BASF (QX)
USI
USTECH100
US Tech 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados